The next generation of skin reconnection technology and will debut at ASLMS 2025 conference
Laval, QC / Access to Newswire / 25 April 2025 / Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), a global, differentiated pharmaceutical company and Aesthetics Business, Solta Medical, announced today by Fraxel FTX ™ to US company Laser Medicine & Surgery, Inc. This event begins the development of Fraxel FTX ™ in dermatologists, plastic surgeons and other licensed aesthetic professionals in the United States, with plans to expand worldwide in the coming months.
Franchise® It is a top treatment in skin rejuvenation, facing common skin concerns, such as sun damage, wrinkles, acne scars and coloring irregularities. With the introduction of the Fraxel FTX ™, the next generation of skin reconnection technology, Bausch Health sets a new standard in lasurfacing with laser skin. Designed to provide an even more expensive, effective and comfortable treatment experience, this next generation product provides dermatologists and aesthetic professionals with advanced tools and is designed to provide remarkable results after a single treatment on all skin types.
“We are pleased to disclose FRAXEL FTX ™ at ASLMS 2025 Conference,” he said Thomas J. Appio, CEO of Bausch Health. “This improved technology marks an important milestone in our commitment to promote aesthetic medicine and enhancing the patient’s experience. FRAXEL FTX ™ incorporates our dedication to providing health professionals with the cutting -edge tools needed to help provide excellent care.”
“Fraxel FTX ™ maintains the reliable, proven laser technology that offers customized treatments to achieve remarkable results, while combining modern design, ergonomic improvements and efficiency to support today’s aesthetic practices,” he said, “he said,” he said, ” Jiny Kim, Senior Vice President, Solta Medical, Bausch Health.
Basic features and benefits of FRAXEL FTX ™:
-
Fractional Laser Double Wave League: Fraxel FTX ™ uses a highly refined fractional laser system that targets aging and skin -damaged skin, leaving the surrounding healthy tissue intact to promote rapid healing. The 1550 Nm glass laser and 1927 Nm Thulium Laser treats surface and deeper layers of skin.
-
Redesigned ergonomic hand: With a 20% decrease in weight and size and new integrated cooling technology, FRAXEL FTX ™ is designed for patient comfort during treatment.
-
Visible results with minimal interruption time: Patients can expect remarkable improvements in skin texture, tone and clarity with minimal disorder in their daily routines.
-
Quick Tracking Experience: Smart visual monitoring® With Accutrac ™ it provides effective and consistent treatment delivery using patent patent technology for effective laser firing.
-
Redesigned console: A modern design with a built -in arm and cable complex.
-
Renewed User Interface: The redesigned color touchscreen and user interface are designed for flexible, personalized treatment settings, supplying aesthetic goals, as well as common skin worries due to damage and aging of the sun.
With the launch of Fraxel FTX ™, Solta Medical continues to drive industry to innovation, providing solutions that aim to help professionals to provide the best results in the class, while improving patient satisfaction.
For more information about FRAXEL FTX ™ and other Solta medical products, visit www.soltamedical.com.
Indications
The FRAXEL FTX ™ laser system indicated for:
-
Franchise® 1550 nm The wavelength is indicated for dermatological processes that require the coagulation of soft tissue. skin repetition procedures. Treatment of difficulty and skin lesions, such as, but are not limited to the lens, solar lens, radial keratotomy and meulas. and the treatment of peripheral wrinkles, acne scars and surgical scars.
-
Franchise® 1927 nm The wavelength is indicated for dermatological processes that require the coagulation of soft tissue. Treatment of radial keratotosis. Treatment of colored lesions, namely lentiga, solar lens and vertices.
Important security information
Contraindications
-
Do not use any patient who is not eligible for general surgery.
-
Pre-examination must include, but not limited to:
-
Predisposition cinoid formation or excessive scars.
-
Changes after surgery.
-
Skin recesses and texture changes after surgery.
-
Systematically (eg prednisone, dexamethasone), which should be strictly avoided before and throughout the treatment.
-
Patients undergoing isotretinoin acne or drugs in a similar class.
-
Medical crisis should be used in the treatment of patients with predisposition After inflammatory hyperchromatism (Pih).
Warnings and warnings
-
Protective glasses or glasses should be worn by any patient, handler and assistant.
-
The medical crisis should be used in the treatment of patients with certain medical conditions.
-
Inappropriate use of Fraxel® may cause injury or damage to the system.
Undesirable events
The Fraxel FTX ™ laser system is only RX. Please refer to the operator manual for detailed instructions, proper use and full risk and safety information. For additional product information see www.fraxel.com/hcp.
CAUTION: Federal law (US) restricts this device to sale from or in the order of a doctor.
To find out more about Fraxel FTX ™ and how it can benefit your practice, contact Solta Medical.
About Bausch’s health
Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) is a global, differentiated pharmaceutical company that enriches lives through our relentless effort to provide better health care results. We develop, manufacture and market a range of products mainly in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health through our interest in Bausch + Lomb. Our ambition is to be a worldwide integrated health care company, reliable and valued by patients, HCP, employees and investors. Our aesthetic business, Solta Medical, is a global aesthetic leader whose vision is to develop and support reliable aesthetic brands that provide value to our customers and patients. More information about Solta Medical can be found in www.solta.com. For more information on bausch health, visit www.bauschhealth.com and log in with us Linkedin.
Future Fulfillments
This press release may contain statements of future fulfillment within the meaning of applicable mobile values laws, including the provisions of secure port provisions of the law on the reform of the differences of US differences in 1995. Variations or similar expressions. These statements are neither historical events nor future performance assurances, are based on the current expectations and beliefs of the administration and are subject to certain dangers and uncertainties that could substantially cause the actual results from those described in future statements. The actual results are subject to other risks and uncertainties that are more widely related to Bausch Health’s overall businesses, including Bausch Health’s most fully described, the most recent annual and quarterly reports by Bausch Health with reference. Readers are warned not to provide excessive dependence on any of these future fulfillment statements. These future statements speak only from the date of the present. The Company does not undertake to inform any of these future fulfillment statements to reflect the facts, information or circumstances after the date of this press release or to reflect the actual results unless required by law.
Investor Contact:
Garen sarafian
ir@bauschhealth.com
(877) 281-6642 (no charge)
Media communication:
Katie savastano
corporate.communications@bauschhealth.com
(908) 569-3692
SOURCE: Bausch Health Companies Inc.
See the original press release In Access Newswire
